<DOC>
	<DOCNO>NCT01338389</DOCNO>
	<brief_summary>Proton beam irradiation treatment choice uveal melanoma . It favorable result cause tumor regression preserve eye . Optic neuropathy emerge consistently irreversible cause visual loss proton beam irradiate eye . No neuroprotective strategy available present . Citicoline choline agent precursor available dietary supplement . Citicoline confer acute neuroprotection enhance neuroplasticity experimental stroke model . In ophthalmology , citicoline demonstrate significant action improve retinal cortical response patient optic nerve disease ( glaucoma , ischemic optic neuropathy ) . Citicoline also exhibit low toxicity profile human . The purpose study demonstrate whether daily oral administration citicoline patient treat uveal melanoma proton beam therapy , prevents delay occurrence radiation optic neuropathy . Changes visual acuity , Pattern ERG visual evoke potential measure . The tolerability/safety product also evaluate .</brief_summary>
	<brief_title>Influence Oral Treatment With Citicoline Prevention Radiation Optic Neuropathy Patients Treated Uveal Melanomas With Proton Beam Therapy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Cytidine Diphosphate Choline</mesh_term>
	<criteria>18 year old uveal melanoma posterior marge locate less 3 mm optic papilla uveal melanoma treat proton beam therapy irradiation optic head nerve visual acuity proton beam therapy 30 letter ( ETDRS test ) antecedent acute glaucoma angle enclosure antecedent chronical glaucoma angle aperture antecedent optic neuropathy optique congenital , ischemic , inflammatory origin antecedent neovascular glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>